US$ 27.23
retatrutide trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Retatrutide FDA Approval Status 2026:
Description
Regul Peptides

Retatrutides body composition data are broadly similar in the Phase 2 results, with the higher total weight loss accompanied by a greater absolute reduction in lean mass
[DOI] [Google Scholar] 5.Dey R.K

Plateau vs
Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart
